Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $117.82 Average Price Target from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $117.8182.

Several equities research analysts recently weighed in on DNTH shares. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush increased their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This trade represents a 86.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,779 shares of company stock worth $7,985,235 in the last ninety days. 3.02% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP raised its position in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the last quarter. TCG Crossover Management LLC increased its stake in Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. Finally, State Street Corp increased its stake in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $104.09 on Friday. The stock has a market cap of $5.69 billion, a PE ratio of -25.20 and a beta of 1.20. The stock’s fifty day moving average is $91.76 and its two-hundred day moving average is $77.61. Dianthus Therapeutics has a 1-year low of $18.08 and a 1-year high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, research analysts expect that Dianthus Therapeutics will post -3.82 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.